L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 562.7 ILS -7.92% Market Closed
Market Cap: 445m ILS
Section:
 

Relative Value

The Relative Value of one LCTX stock under the Base Case scenario is 411.34 ILS. Compared to the current market price of 562.7 ILS, Lineage Cell Therapeutics Inc is Overvalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LCTX Relative Value
Base Case
411.34 ILS
Overvaluation 27%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

12.5
P/S
P/S
Price to Sales
12.5
vs History
26
vs Industry
73
Median 3Y
8.2
Median 5Y
10.2
Industry
7.6
Forward
15.4
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-3.3
Median 5Y
-3.4
Industry
24.3
Forward
-3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-3.3
Industry
22
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-3.1
Median 5Y
-2.9
Industry
24.3
More Details
2.8
P/B
P/B
Price to Book Value
2.8
vs History
0
vs Industry
74
Median 3Y
1.3
Median 5Y
1.4
Industry
3.2
More Details
8.6
EV/S
EV/S
Enterprise Value to Sales
8.6
vs History
25
vs Industry
29
Median 3Y
4
Median 5Y
4.9
Industry
8.4
Forward
10.7
More Details
8.8
EV/GP
EV/GP
Enterprise Value to Gross Profit
8.8
vs History
25
vs Industry
26
Median 3Y
4.3
Median 5Y
5.5
Industry
10.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
18
Median 3Y
-1.8
Median 5Y
-2
Industry
6.2
Forward
-2.5
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
16
Median 3Y
-1.7
Median 5Y
-2
Industry
6.7
Forward
-2.3
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
21
Median 3Y
-1.6
Median 5Y
-1.8
Industry
8.1
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
17
Median 3Y
-1.6
Median 5Y
-1.7
Industry
6.6
More Details
2
EV/IC
EV/IC
Enterprise Value to IC
2
vs History
7
vs Industry
45
Median 3Y
0.7
Median 5Y
0.8
Industry
5.3
More Details

Multiples Across Competitors

LCTX Competitors Multiples
Lineage Cell Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Lineage Cell Therapeutics Inc
TASE:LCTX
445m ILS 12.5 -3.3 -4.8 -4.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 246 369.5 -162 767.9 -197 652.2 -195 396.7
US
Abbvie Inc
NYSE:ABBV
413.6B USD 6.9 176.2 17 24.1
US
Amgen Inc
NASDAQ:AMGN
183.9B USD 5.1 26.3 18.8 18.8
US
Gilead Sciences Inc
NASDAQ:GILD
156.4B USD 5.4 19.3 13 13
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.6B USD 9.4 30.1 22 23
US
Epizyme Inc
F:EPE
94.1B EUR 2 057.1 -524.9 -571.6 -556.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.1B USD 5.3 16.4 15.6 17.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
60.6B USD 24.6 -189.9 -475.2 -326.2
AU
CSL Ltd
ASX:CSL
87.2B AUD 3.6 18.9 12.8 15.9
NL
argenx SE
XBRU:ARGX
48.8B EUR 15.7 36.9 64 65.8
P/E Multiple
Earnings Growth PEG
US
L
Lineage Cell Therapeutics Inc
TASE:LCTX
Average P/E: 46.3
Negative Multiple: -3.3 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 767.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
176.2
89%
2
US
Amgen Inc
NASDAQ:AMGN
26.3
44%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19.3
191%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.1
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -524.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.4
8%
2.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -189.9 N/A N/A
AU
CSL Ltd
ASX:CSL
18.9
11%
1.7
NL
argenx SE
XBRU:ARGX
36.9
37%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
L
Lineage Cell Therapeutics Inc
TASE:LCTX
Average EV/EBITDA: 23.3
Negative Multiple: -4.8 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 652.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.8
10%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -571.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.6
9%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -475.2 N/A N/A
AU
CSL Ltd
ASX:CSL
12.8
8%
1.6
NL
argenx SE
XBRU:ARGX
64
769%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
L
Lineage Cell Therapeutics Inc
TASE:LCTX
Average EV/EBIT: 25.5
Negative Multiple: -4.6 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 396.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.8
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
13
13%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
17%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
12%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -326.2 N/A N/A
AU
CSL Ltd
ASX:CSL
15.9
11%
1.4
NL
argenx SE
XBRU:ARGX
65.8
N/A N/A

See Also

Summary
LCTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LCTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LCTX stock valuation using valuation multiples.
Wall Street Estimates
LCTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LCTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 297,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.